Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
80%(4 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
4
80%

Phase Distribution

1

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 34 (80.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04829344
completedphase_3

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

NCT05501860
completedphase_3

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

NCT05325853
completedphase_3

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04513652
completedphase_1

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

NCT04759339

Clinical Trials (5)

Showing 5 of 5 trials
NCT04829344Phase 3

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Completed
NCT05501860Phase 3

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

Completed
NCT05325853Phase 3

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

Completed
NCT04513652Phase 3

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Completed
NCT04759339Phase 1

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5